Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation site inhibitor YY201 successfully compl

Recently, YY201, a STAT3 dual phosphorylation site inhibitor independently developed by Yuyao Biotech, was approved by the US FDA and agreed to conduct Phase I clinical studies for malignant hematological tumors.  This is another milestone after YY201 IND was approved by China's NMPA in July 2023. It is also an important step for Yuyao Biotech to move towards globalization and international development with its independently built first-class technology platform and leading product pipeline.

Learn more about Medicilon's STAT3-targeted Drugs R&D Services.

Shanghai Medicilon Inc. (Medicilon), as a partner of Yuyao Biotech, provided YY201 with pharmaceutical research services (including APIs and preparations), preclinical research services (including efficacy, pharmacokinetics, safety evaluation), and IND application services, which helped YY201 successfully complete dual submissions in China and US.

Tackle the most cutting-edge new drug research and development technologies 

Medicilon continues to iterate its one-stop preclinical R&D service platform

Innovate technology ahead of clients and lay out plans ahead of industry needs.  In the past two decades, Medicilon has continued to increase investment in R&D, focusing on cutting-edge fields such as nucleic acid drugs, cellular immunity, mRNA vaccines, PROTAC, ADC, and bi/multi-specific antibodies, building an innovative R&D service platform, and continuing to iterate and update, to help more "First-in-class" drugs successfully enter clinical trial and achieve dual approval in China and US.

About Yuyao Biotech

Yuyao Biotechnology is a new drug research and development enterprise empowered by AI, led by innovation, and focusing on new technologies and new targets.  The company has three world-class new drug research and development platforms and multiple independent original product pipelines, and the core products are currently undergoing clinical research registration.  The product pipeline, YY001, targets the tumor immune microenvironment to treat PD-1 antibody-sensitive and insensitive advanced solid tumors, is about to start Phase 2 clinical research and has the potential to become the world's best immune microenvironment antagonist.  The product YY201 is the world's first transcription factor inhibitor, which is about to start phase 1 clinical research in China and the United States, and other product pipelines will soon enter clinical trials in the future.  The company has applied for more than 20 invention patents and has entered Europe, the United States, Japan, Canada, and Australia through PCT international applications.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 385 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.